^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BGB-30813

    i
    Other names: BGB-30813, BGB30813, BGB 30813
    Associations

    News

    Trials
    Company:
    BeOne Medicines
    Drug class:
    DGKZ inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=44, Terminated, BeiGene | Trial completion date: Dec 2025 --> Aug 2025 | Active, not recruiting --> Terminated; The Sponsor has made the decision to discontinue the clinical development of BGB-30813 and close the study based on imbalanced benefit/risk profile in the BGB-A317-30813-101 study.
    Trial completion date • Trial termination
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • BGB-30813
    6ms
    A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, BeiGene | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Dec 2026 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • BGB-30813
    9ms
    A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | N=200 --> 44
    Enrollment closed • Enrollment change
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • BGB-30813
    1year
    A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=200, Recruiting, BeiGene | Active, not recruiting --> Recruiting | N=37 --> 200 | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • BGB-30813
    over1year
    A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | N=209 --> 37
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    Tevimbra (tislelizumab-jsgr) • BGB-30813
    2years
    A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 (clinicaltrials.gov)
    P1, N=209, Recruiting, BeiGene | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • BGB-30813
    over2years
    A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 (clinicaltrials.gov)
    P1a/1b, N=289, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • BGB-30813
    over2years
    A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 (clinicaltrials.gov)
    P1a/1b, N=289, Not yet recruiting, BeiGene
    New P1 trial • Combination therapy • Metastases
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • BGB-30813